Biodexa Pharmaceuticals plc
As of Oct 22, 2026, Biodexa Pharmaceuticals is in Stage 4, the downtrend phase, now in week 48 (since Nov 13, 2025). It closed at $0.41, 99.1% below its 52-week high and below its 200-day average, which is falling.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder c… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BDRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BDRX among Biotechnology546th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …546 | BDRX | Stage 4 · wk 48 | 3 | −39.9% |
Biodexa Pharmaceuticals: quick answers
What stage is Biodexa Pharmaceuticals in?
As of Oct 22, 2026, Biodexa Pharmaceuticals (BDRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 13, 2025 and is in week 48. What the four stages mean
Is Biodexa Pharmaceuticals in an uptrend?
No. Biodexa Pharmaceuticals is in a Stage 4 downtrend. It trades 88.2% below its 200-day average, which is falling.
How far is Biodexa Pharmaceuticals from its 52-week high?
Biodexa Pharmaceuticals closed at $0.41 on Oct 22, 2026, 99.1% below its 52-week high of $44.00. Its 52-week low is $0.35.
How has Biodexa Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Biodexa Pharmaceuticals is down 98.9% over the past year and down 96.6% so far in 2026.
Which sector and industry is Biodexa Pharmaceuticals in?
Biodexa Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.